Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome.

Familial cancer - 1 Jul 2022

Oba Leatrisse, Best Ana F, Mai Phuong L, Achatz Maria Isabel, Albert Paul S, Savage Sharon A, Khincha Payal P

Abstract excerpt

Comprehensive annual screening reduces cancer-related mortality in Li-Fraumeni syndrome (LFS), a cancer-prone disorder caused by pathogenic germline TP53 variants. Blood tests at months 4 and 8 between annual screening are recommended but their effectiveness in early cancer detection has not been established. Interim blood counts and inflammatory biomarkers were evaluated in 132 individuals with LFS (112 adults,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child, Preschool
Share to Early Detection of Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Germ-Line Mutation

Share to Hematologic Tests

Share to Infant

Share to Li-Fraumeni Syndrome

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 34076823
DOI: 10.1007/s10689-021-00265-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome.PMID 34076823Read ↗

Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.Semantic proximity Read ↗

Inherited TP53 Mutations and the Li-Fraumeni Syndrome.Semantic proximity Read ↗

Current insights and future directions of Li-Fraumeni syndromeSemantic proximity Read ↗

Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.Semantic proximity Read ↗

Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome.Semantic proximity Read ↗

Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriersSemantic proximity Read ↗

New Paradigms in the Clinical Management of Li-Fraumeni Syndrome.Semantic proximity Read ↗

Rates of Intervention and Cancer Detection on Initial versus Subsequent Whole-body MRI Screening in Li-Fraumeni Syndrome.Semantic proximity Read ↗

Li-Fraumeni Syndrome: An In-depth OverviewSemantic proximity Read ↗

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.Semantic proximity Read ↗

F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.Semantic proximity Read ↗

Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.